Stephanie Hugghins Shah, MD Internal Medicine - Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 2692 W Walnut St Ste 207, Garland, TX 75042 Phone: 214-403-0682 |
News Archive
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced positive, statistically significant data from the Company's Phase 1 clinical trial evaluating the safety and tolerability of RenaZorb (also referred to as SPI-014) in healthy volunteers.
Hollis-Eden Pharmaceuticals, Inc., today reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). Presented at the Molecular Targets and Cancer Therapeutics Conference, which is co-sponsored by the AACR, NCI and EORTC, the poster is titled: "Results of preclinical and clinical Phase I/II open-label dose-ranging trial with HE3235, a synthetic adrenal hormone, in Castrate Resistant Prostate Cancer (CRPC)."
Vical Incorporated today announced that an independent Safety Monitoring Board (SMB) for the company's Phase 3 trial of Allovectin-7® in patients with metastatic melanoma has completed the trial's fourth scheduled safety analysis and recommended that the trial continue per the protocol.
Researchers found that a low carbohydrate diet that reduced total caloric intake by 30% prevented the development of a fundamental feature of Alzheimer's disease (AD) in mice genetically engineered to develop the disease. The diet eliminated amyloid plaque development, which is the underlying pathology in AD.
› Verified 8 days ago